|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shackelford RE, Mayhall K, Maxwell NM,
Kandil E and Coppola D: Nicotinamide phosphoribosyltransferase in
malignancy: A review. Genes Cancer. 4:447–456. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bi TQ and Che XM: Nampt/PBEF/visfatin and
cancer. Cancer Biol Ther. 10:119–125. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chini CC, Guerrico AM, Nin V,
Camacho-Pereira J, Escande C, Barbosa MT and Chini EN: Targeting of
NAD metabolism in pancreatic cancer cells: Potential novel therapy
for pancreatic tumors. Clin Cancer Res. 20:120–130. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Folgueira MA, Carraro DM, Brentani H,
Patrão DF, Barbosa EM, Netto MM, Caldeira JR, Katayama ML, Soares
FA, Oliveira CT, et al: Gene expression profile associated with
response to doxorubicin-based therapy in breast cancer. Clin Cancer
Res. 11:7434–7443. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bi TQ, Che XM, Liao XH, Zhang DJ, Long HL,
Li HJ and Zhao W: Overexpression of Nampt in gastric cancer and
chemopotentiating effects of the Nampt inhibitor FK866 in
combination with fluorouracil. Oncol Rep. 26:1251–1257.
2011.PubMed/NCBI
|
|
8
|
Long HL, Che XM, BI TQ, Li HJ, Liu JS and
Li DW: The expression of nicotinamide phosphoribosyl transferase
and vascular endothelial growth factor-A in gastric carcinoma and
their clinical significance. Zhonghua Wai Ke Za Zhi. 50:839–842.
2012.PubMed/NCBI
|
|
9
|
Tavassoli FA: Pathology of the Breast.
McGraw-Hill Medical; New York, NY, USA: pp. 254–397. 1999
|
|
10
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th ed. New
York: Springer; 2010
|
|
11
|
Maldi E, Travelli C, Caldarelli A,
Agazzone N, Cintura S, Galli U, Scatolini M, Ostano P, Miglino B,
Chiorino G, et al: Nicotinamide phosphoribosyltransferase (NAMPT)
is over-expressed in melanoma lesions. Pigment Cell Melanoma Res.
26:144–146. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Olesen UH, Hastrup N and Sehested M:
Expression patterns of nicotinamide phosphoribosyltransferase and
nicotinic acid phosphoribosyltransferase in human malignant
lymphomas. APMIS. 119:296–303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakajima TE, Yamada Y, Hamano T, Furuta K,
Gotoda T, Katai H, Kato K, Hamaguchi T and Shimada Y: Adipocytokine
levels in gastric cancer patients: Resistin and visfatin as
biomarkers of gastric cancer. J Gastroenterol. 44:685–690. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakajima TE, Yamada Y, Hamano T, Furuta K,
Matsuda T, Fujita S, Kato K, Hamaguchi T and Shimada Y:
Adipocytokines as new promising markers of colorectal tumors:
Adiponectin for colorectal adenoma, and resistin and visfatin for
colorectal cancer. Cancer Sci. 101:1286–1291. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang B, Hasan MK, Alvarado E, Yuan H, Wu H
and Chen WY: NAMPT overexpression in prostate cancer and its
contribution to tumor cell survival and stress response. Oncogene.
30:907–921. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu Y, Guo M, Zhang L, Xu T, Wang L and Xu
G: Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection
panel for the diagnosis and prognosis of human breast cancer. Oncol
Rep. 35:454–462. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Santidrian AF, LeBoeuf SE, Wold ED,
Ritland M, Forsyth JS and Felding BH: Nicotinamide
phosphoribosyltransferase can affect metastatic activity and cell
adhesive functions by regulating integrins in breast cancer. DNA
Repair. 23:79–87. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Domagala P, Huzarski T, Lubinski J, Gugala
K and Domagala W: PARP-1 expression in breast cancer including
BRCA1-associated, triple negative and basal-like tumors:
Possible implications for PARP-1 inhibitor therapy. Breast Cancer
Res Treat. 127:861–869. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li D, Bi FF, Chen NN, Cao JM, Sun WP, Zhou
YM, Li CY and Yang Q: A novel crosstalk between BRCA1 and poly
(ADP-ribose) polymerase 1 in breast cancer. Cell Cycle.
13:3442–3449. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bajrami I, Kigozi A, van Weverwijk A,
Brough R, Frankum J, Lord CJ and Ashworth A: Synthetic lethality of
PARP and NAMPT inhibition in triple-negative breast cancer cells.
EMBO Mol Med. 4:1087–1096. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Samal B, Sun Y, Stearns G, Xie C, Suggs S
and McNiece I: Cloning and characterization of the cDNA encoding a
novel human pre-B-cell colony-enhancing factor. Mol Cell Biol.
14:1431–1437. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jia SH, Li Y, Parodo J, Kapus A, Fan L,
Rotstein OD and Marshall JC: Pre-B cell colony-enhancing factor
inhibits neutrophil apoptosis in experimental inflammation and
clinical sepsis. J Clin Invest. 113:1318–1327. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou T, Wang T and Garcia JG: Expression
of nicotinamide phosphoribosyltransferase-influenced genes predicts
recurrence-free survival in lung and breast cancers. Sci Rep.
4:61072014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hong SM, Park CW, Kim SW, Nam YJ, Yu JH,
Shin JH, Yun CH, Im SH, Kim KT, Sung YC and Choi KY: NAMPT
suppresses glucose deprivation-induced oxidative stress by
increasing NADPH levels in breast cancer. Oncogene. 35:3544–3554.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zerp SF, Vens C, Floot B, Verheij M and
van Triest B: NAD+ depletion by APO866 in combination
with radiation in a prostate cancer model, results from an in vitro
and in vivo study. Radiother Oncol. 110:348–354. 2014. View Article : Google Scholar : PubMed/NCBI
|
